These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11286939)

  • 1. Tumorigenesis in neurofibromatosis: new insights and potential therapies.
    Reed N; Gutmann DH
    Trends Mol Med; 2001 Apr; 7(4):157-62. PubMed ID: 11286939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurofibromatoses: when less is more.
    Gutmann DH
    Hum Mol Genet; 2001 Apr; 10(7):747-55. PubMed ID: 11257108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic and molecular pathogenesis of NF1 and NF2.
    Yohay KH
    Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing biologically targeted clinical trials for neurofibromatosis.
    Gutmann DH; Blakeley JO; Korf BR; Packer RJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):443-62. PubMed ID: 23425047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofibromatosis and associated tumour suppressor genes.
    Zwarthoff EC
    Pathol Res Pract; 1996 Jul; 192(7):647-57. PubMed ID: 8880865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the neurofibromatoses.
    Gutmann DH
    Curr Opin Neurol; 1994 Apr; 7(2):166-71. PubMed ID: 8019663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse models of neurofibromatosis 1 and 2.
    Gutmann DH; Giovannini M
    Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
    Tamura R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2).
    Shen YC; Arellano-Garcia C; Menjivar RE; Jewett EM; Dohle W; Karchugina S; Chernoff J; Potter BVL; Barald KF
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):67. PubMed ID: 31730023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF2: the wizardry of merlin.
    Xiao GH; Chernoff J; Testa JR
    Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis-related tumors: emerging biology and therapies.
    Karajannis MA; Ferner RE
    Curr Opin Pediatr; 2015 Feb; 27(1):26-33. PubMed ID: 25490687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
    Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
    Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibromatosis 1: closing the GAP between mice and men.
    Dasgupta B; Gutmann DH
    Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of signal transduction in genetically driven sarcomas of the nerve.
    Kim A; Pratilas CA
    Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurofibromatosis type 2 (NF2)].
    Araki N; Takeshima H; Saya H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
    Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
    J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofibromatosis.
    McClatchey AI
    Annu Rev Pathol; 2007; 2():191-216. PubMed ID: 18039098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
    Feldkamp MM; Angelov L; Guha A
    Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.